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James K. Min, MD,* Y. Chandrashekhar, MD,y Jagat Narula, MD, PHDzThe times, they are a-changin’.
—Bob Dylan (1)A lmost 20 years ago, fractional ﬂow reserve(FFR) assessment performed at the time ofinvasive coronary angiography (ICA) was
introduced as a method for identifying and excluding
stenoses that reduced epicardial coronary artery ﬂow
(2). FFR was deﬁned as the ratio of maximal coronary
blood ﬂow through a diseased artery to maximal coro-
nary ﬂow in the hypothetical case that the artery was
normal. A 20% reduction in coronary ﬂow has been
used in the recent outcome studies of revasculariza-
tion as a threshold below which coronary ischemia
were considered present (3,4).
An array of validation studies have established the
efﬁcacy of FFR for different coronary artery disease
(CAD) patterns, including anatomically high-grade
coronary stenoses, elongated lesions of intermediate
stenoses, and even nonobstructive lesions with large
necrotic cores (5,6). These studies have emphasized
the complex relationship between stenosis severity
and coronary ischemia, wherein about 20% of
anatomically severe stenoses $70% do not cause
ischemia and >15% of anatomically nonsevere
stenoses <50% do cause ischemia (6).
That FFR improves event-free survival has been
consistently established in several large-scale ran-
domized controlled trials (3,4). These outcomes
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by FFR evaluation to be safe. Importantly, these
ﬁndings hold true whether FFR-guided PCI is
compared with stenosis-guided PCI or with optimal
medical therapy. The current societal guidance docu-
ments assign a class IA recommendation for FFR use
for stenoses between 50% and 90% to verify the
presence of ischemia before the performance of PCI
(7). It is intriguing that the strategy of FFR evaluation
has been so effective in the management of CAD. This
is a complex question, one whose answer consists of
several interrelated features. One essential consider-
ation is that FFR assessment in association with ICA
represents a hybrid anatomico-physiologic diagnostic
method for CAD evaluation. There is emerging evi-
dence that FFR might also reﬂect plaque morphology
and exclude the likelihood of high-risk plaqueswhen it
exceeded a threshold value of 0.8. This integration of
anatomic, physiological, and pathological CAD ﬁnd-
ings encourages the diagnosis of coronary ischemia in
a lesion-speciﬁc fashion and serves as a standard on
which noninvasive approaches can be modeled (8).
Fractional ﬂow reserve derived from coronary
computed tomographic angiography (FFRCT) is a
novel noninvasive method for the identiﬁcation and
exclusion of ischemia-causing coronary artery lesions
(9). FFRCT quantiﬁes a series of form-function re-
lationships and applies computational ﬂuid dynamics
to computed tomographic angiographic (CTA) images
for the calculation of FFR at any point in the epicar-
dial coronary vascular bed. Importantly, FFRCT is
calculated using typically acquired CTA studies and
thus does not require additional imaging, modiﬁca-
tion of image acquisition protocols, administration of
vasodilators, or additional radiation. Given its recent
approval by the U.S. Food and Drug Administration in
late 2014, it is timely to consider its role in the eval-
uation of patients with suspected CAD.
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1118Like its invasive FFR and ICA counterparts, FFRCT
is necessarily coupled to CTA and thus represents a
hybrid anatomic-physiological diagnostic method;
additionally, CTA can elaborate on plaquemorphology
comparably with intravascular ultrasound assessment
(10). As with invasive methods addressing issues of
coronary revascularization, the optimal noninvasive
approach requires a stepwise logical resolution of at
least 7 essential questions that relate directly to issues
of diagnostic accuracy, prognosis, ischemia, predic-
tion of therapeutic beneﬁt, and cost-effectiveness:
 Is CAD present, and does this CAD demonstrate
concordance with invasive methods?
 Does the CAD identiﬁed predict future adverse
outcomes, and does intervention reduce these
events?
 If CAD is present, is there a coronary artery stenosis
that reduces coronary blood ﬂow?
 If a coronary stenosis reduces blood ﬂow, will
revascularization of the stenosis reduce ischemia?
 If revascularization will reduce the ischemia, what
is the best method and approach to doing so?
 Does revascularization of ischemia-causing coro-
nary stenoses improve event-free survival?
 If so, is the noninvasive approach cost effective?
The diagnostic accuracy and prognostic utility of
CTA ﬁndings of anatomic CAD have been well exam-
ined (11,12). Three prospective multicenter trials have
demonstrated CTA, compared with an ICA reference
standard, to have exceptional sensitivity and mod-
erate speciﬁcity for CAD detection and exclusion, the
latter highlighting a non-negligible rate of false-
positive studies wherein stenosis severity by CTA is
often overestimated (13,14). CAD, as detected by CTA,
imparts valuable prognostic information that iden-
tiﬁes at-risk patients who will experience future ma-
jor adverse cardiovascular events or death. Of
perhaps equal importance, CTA enables the identiﬁ-
cation of subclinical “mild” coronary artery lesions,
whose atherosclerotic burden and features are also
associated with poorer outcomes. For both mild as
well as severe CAD by CTA, medical therapies are
associated with both reduced progression of CAD and
improved clinical outcomes (15,16).
Unique to FFRCT is the manner by which it iden-
tiﬁes hemodynamically signiﬁcant CAD, given the
inability of both anatomic (CTA or ICA) and physio-
logical (single-photon emission computed tomogra-
phy, stress echocardiography, etc.) tests alone to
precisely identify and discriminate ischemia-causing
coronary lesions. Indeed, >50% of lesions consid-
ered high grade by CTA manifest no ischemia, and
>50% of patients referred for ICA on the basis ofstress testing do not manifest anatomically obstruc-
tive CAD. To date, 3 prospective multicenter trials
have evaluated the diagnostic performance of FFRCT
to identify ischemia compared with an invasive FFR
standard (8,17,18). These study designs—using itera-
tively newer generation FFRCT technologies—are a
welcome deviation from prior studies evaluating
other noninvasive tests, which have principally
evaluated test performance against an anatomic ICA
standard rather than FFR. Furthermore, FFRCT per-
formance was tested for its ability to identify both
patient-level ischemia and coronary lesion–speciﬁc
ischemia. Given its inextricable link to CTA, which
facilitates visualization of coronary stenoses, the
latter is a condition not evaluable by any other
noninvasive technique. In the most recent NXT
(Analysis of Coronary Blood Flow Using CT Angiog-
raphy: Next Steps) trial, FFRCT demonstrated overall
diagnostic accuracy of 86% compared with FFR,
which establishes its robust performance as well as its
superiority to historical reports for single-photon
emission computed tomographic myocardial perfu-
sion imaging and stress echocardiography.
Despite its apparent higher diagnostic accuracy
compared with other noninvasive approaches, few
data exist for FFRCT for prediction of therapeutic
beneﬁt, improvement of event-free survival, or cost-
effectiveness. Because FFRCT is a computational
model, the therapeutic beneﬁt of “virtual” PCI and
coronary artery bypass surgery can be modeled to
predict effect on ischemia improvement. In a pilot
study, Koo et al. (17) evaluated the ability of FFRCT to
predict therapeutic beneﬁt of PCI, observing the
diagnostic accuracy of “virtual stenting” to be 96%
compared with pre- and post-PCI invasive FFR. This
concept will be tested further in the CREDENCE
(Computed Tomographic Evaluation of Atheroscle-
rotic Determinants of Myocardial Ischemia) trial, a 20-
site study of 618 patients (NCT02173275) (19). The
comparative beneﬁts of “virtual stenting” versus
“virtual coronary artery bypass surgery,” although
theoretically possible, have not been evaluated to
date.
Clinical and economic outcomes for FFRCT have
been assessed in a decision-analytic model but not
yet reported in any study. These features are being
evaluated in PLATFORM (Prospective Longitudinal
Trial of FFRCT: Outcome and Resource Impacts), a
584-patient prospective controlled utility trial eval-
uating patients with intermediate likelihood of CAD
who are being referred for noninvasive evaluation
(ﬁrst cohort) or ICA (second cohort) (NCT01943903).
Longitudinally, sites will evaluate patients using
standard-of-care approaches (ﬁrst phase) and then a
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1119CTA- and FFRCT-based approach (second phase). The
primary endpoint of PLATFORM will be rates of ICA
without obstructive CAD, with important secondary
endpoints related to costs, resource utilization,
quality of life, and radiation exposure. Results are
anticipated shortly. Given the recent introduction of
FFRCT in 2011, no long-term or outcomes-based clin-
ical trials have been reported.
Beyond these essential diagnostic testing criteria,
several other practical factors require consideration
for FFRCT. At present, FFRCT is offered as software as
a service model, whereby CTA obtained at clinical
sites are sent electronically off site for calculation of
FFRCT. Given the computationally intense approach
to calculate FFRCT, present turnaround times are up
to 2 days for FFRCT results. This signiﬁcantly chal-
lenges traditional clinical work ﬂows whereby both
patient and physician would like to consider the
anatomic and physiological CAD ﬁndings together,
rather than sequentially. This temporal uncoupling of
the anatomic CTA and the physiological FFRCT raises
important concerns. With perpetual improvements
in computational power, it also remains to be seen
whether FFRCT will be offered in the future using
on-site workstation-based software solutions. At
present, there is an absence of workstation-based
software for proper mesh generation and subvoxel
resolutions required for FFRCT calculations using 3-
dimensional computational ﬂuid dynamics methods.
Other reduced-order workstation-based software so-
lutions for calculation of FFR from CTA have been
reported, with promising data, but are not yet com-
mercially available. In addition, image quality re-
mains a similarly important issue. Common CTA
artifacts, such as misregistration and motion, de-
crease the accuracy of FFRCT, and the proportion
of nonevaluable CTA for FFRCT calculation is un-
known. Interestingly, FFRCT appears to be immune tocoronary calcium extent and severity. Yet in prior
diagnostic performance studies of FFRCT, rates of
nonevaluability mirrored those of CTA in multicenter
trials (w10% to 15%).
The aforementioned topics represent only a small
number of the many scientiﬁc and logistic consider-
ations for the use of FFRCT in daily clinical practice.
Outstanding questions informing its most appropriate
use will likely require further evaluation in more
deﬁned cohorts (e.g., patients with known CAD),
head-to-head demonstrations of superiority to con-
ventional diagnostic approaches, and authentication
of the ability of FFRCT to predict the therapeutic
beneﬁt of coronary revascularization and improve
associated clinical outcomes. Yet similar to the
hybrid anatomic-physiological approach of ICA
and FFR, the hybrid approach of CTA (including
description of plaque morphology) and FFRCT offers
the promise that the combination of these nonin-
vasive technologies can serve as an effective strat-
egy that will enable the detection of ischemia,
precise identiﬁcation of the coronary lesions that
are the cause, and determination of the most ef-
fective treatment strategies at a coronary artery
lesion–speciﬁc level. Each of these features is a
unique and welcome addition to the capabilities of
noninvasive imaging, and they challenge traditional
methods of evaluation that include ischemia testing
or CTA alone. How FFRCT will build on the optimal
approach to the diagnosis of CAD and where it will
change daily clinical practice remain to be observed,
but what is certain is that the times, they are
a-changin’.
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